The Apnea Risk Evaluation System (ARES™) integrates physiological data acquired in-home with clinical history and anthropomorphic data to determine the presence and severity of Obstructive Sleep Apnea (OSA). ARES™ has been cleared for use by the United States Food and Drug Administration (FDA), and is ISO 13485 certified for Europe and Canada.
ARES™ Home Sleep test Device integrates:
A sleep-wearable, wireless physiological recorder worn on the forehead that acquires and stores up to 3 nights of nocturnal data. ARES™ measures blood oxygen saturation (SpO2) and pulse rate (reflectance pulse oximetry), airflow (by nasal cannula connected to a pressure transducer), snoring levels (calibrated acoustic microphone), head movement and head position (accelerometers). When worn in the home, the ARES™ provides a better profile of the patient's breathing during sleep in his/her normal environment. Audio and visual indicators notify the user when the ARES™ requires adjustment, thus increasing reliability of the device in the home. The small size of ARES™ allows it to be comfortably worn in all sleep positions.
A validated predictor of OSA risk (those in need of a sleep study based on a predicted apnea/hypopnea index > 5 events/hour) and OSA severity (i.e., minimal, mild, moderate or severe) using responses to questions about body type, symptoms of daytime drowsiness, snoring, and other sleep-related characteristics or health conditions associated with OSA. The results can be used to rapidly screen large populations to determine a prior probability of obstructive sleep apnea (OSA). The results are also used to supplement the physiological data obtained in the ARES Sleep Apnea Study.